Tofacitinib for people with ALS and a specific immune profile
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests a drug called tofacitinib, which calms the immune system, in people with ALS. It aims to see if it can slow the disease by blocking an overactive immune response linked to certain genetic patterns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have a confirmed diagnosis of ALS (using the Gold Coast criteria)
- Your lung function (forced vital capacity) is at least 60% of the predicted normal value
- A special genetic test shows your immune system has high activity in certain cells (CD8+ T cells and Th1 cells) and that nerve repair pathways are not strongly blocked
- You are willing to use effective contraception if you could become pregnant or father a child
- You do not have serious infections, low blood counts, or significant liver, kidney, or heart problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests RAPA-501, a treatment made using your own immune cells, to slow progression of ALS. It may help by changing how your immune system responds in ALS.
This trial tests whether a drug called tazbentetol can help people with ALS. It aims to see if it is safe and slows the disease's progression.
This trial tests if the drug tofacitinib can help people whose heart inflammation from cancer immunotherapy (called ICI-related myocarditis) does not improve with steroids. If you have this condition, this study may offer a new treatment option.
This trial tests whether tofacitinib (a pill that reduces inflammation) can help people with early-stage axial spondyloarthritis, a type of arthritis that mainly affects the spine and pelvis. It's for those who have had symptoms for 2 years or less and have active disease with signs of inflammation in MRI or blood tests.
This trial tests if tofersen, a drug that targets a protein linked to ALS, can help people who have ALS but do not have mutations in the SOD1 or FUS genes. It aims to slow disease progression in those diagnosed within the last 2 years.
This trial tests the drug tofacitinib in children with juvenile idiopathic arthritis (a type of arthritis that starts before age 18). It looks at whether tofacitinib is a safe and effective treatment for this condition.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.